- Home
- PYPD vs SPAI Comparison
PYPD vs SPAI Comparison
Compare PYPD & SPAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PYPD | SPAI |
|---|---|---|
| Founded | 2008 | 2021 |
| Country | Israel | United States |
| Employees | N/A | 15 |
| Industry | Medical/Dental Instruments | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 77.5M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | PYPD | SPAI |
|---|---|---|
| Price | $3.92 | $3.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $12.25 | $10.00 |
| AVG Volume (30 Days) | ★ 333.3K | 85.4K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,060.58 |
| Revenue Next Year | N/A | $162.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.06 | $2.86 |
| 52 Week High | $5.73 | $9.16 |
Technical Indicators
Market Signals| Indicator | PYPD | SPAI |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 36.87 |
| Support Level | $3.50 | $3.39 |
| Resistance Level | $4.44 | $4.74 |
| Average True Range (ATR) | 0.44 | 0.24 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 12.02 | 13.83 |
Price Performance
Historical ComparisonAbout PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About SPAI Safe Pro Group Inc.
Safe Pro Group Inc operates to acquire security and protection products. The company operated in three reportable business segments, which consisted of the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. The majority of revenue is from Safe-Pro USA.